The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2024
Filed:
Jan. 04, 2021
Applicant:
Integrated Dna Technologies, Coralville, IA (US);
Inventors:
Joseph Dobosy, Coralville, IA (US);
Caifu Chen, Palo Alto, CA (US);
Mark Aaron Behlke, Coralville, IA (US);
Garrett Richard Rettig, Coralville, IA (US);
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC., Coralville, IA (US);
Primary Examiner:
Int. Cl.
CPC ...
C12P 19/34 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12Q 1/6827 (2018.01); C12Q 1/6853 (2018.01); C12Q 1/6858 (2018.01); C12Q 1/6876 (2018.01); G16B 20/20 (2019.01); G16B 30/00 (2019.01); C12N 9/12 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6827 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12Q 1/6853 (2013.01); C12Q 1/6858 (2013.01); C12Q 1/6876 (2013.01); C12Y 207/07007 (2013.01); C12Y 301/00 (2013.01); C12Y 301/26004 (2013.01); G16B 20/20 (2019.02); G16B 30/00 (2019.02); C07K 2319/21 (2013.01); C12N 9/1252 (2013.01); C12N 2310/20 (2017.05); C12Q 2521/327 (2013.01); C12Q 2525/121 (2013.01); C12Q 2525/155 (2013.01); C12Q 2525/161 (2013.01); C12Q 2525/185 (2013.01); C12Q 2525/186 (2013.01); C12Q 2535/125 (2013.01); C12Q 2600/156 (2013.01);
Abstract
Methods for detecting on-target and predicted off-target genome editing events by providing a multiplex PCR reaction mixture with an on-target oligonucleotide primer and one or more off-target oligonucleotide primers and then hybridizing the on-target oligonucleotide primer and the one or more off-target oligonucleotide primers to target nucleic acid sequences, followed by cleaving blocking groups from the primers and extending the primers.